1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,265 | 3,600 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application | 127 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 61 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.01. | XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025 | 94 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology... ► Artikel lesen | |
| 14.11.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB | 311 | GlobeNewswire | With effect from November 15, 2024, the subscription rights of Xspray Pharma
AB will be traded on the list for Equity rights. Trading will continue up until
and including November 26, 2024.
Instrument:... ► Artikel lesen | |
| 12.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.2024 | 2.271 | Xetra Newsboard | Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Interim Report Third Quarter 2024 | 132 | GlobeNewswire (Europe) | July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million | 179 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 19.09.24 | Xspray Pharma AB: Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission | 309 | Business Wire | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology to develop enhanced cancer therapies, today announced significant progress... ► Artikel lesen | |
| 06.09.24 | Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology | 433 | Business Wire | A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap technology improves the bioavailability and reduces variability of... ► Artikel lesen | |
| 07.08.24 | XSpray Pharma AB: Interim Report Second Quarter 2024 | 151 | GlobeNewswire (Europe) | April-June 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -53,620 thousand (-51,402)Earnings per share before dilution amounted to SEK -1.64 (-2.27)Cash flow from... ► Artikel lesen | |
| 26.07.24 | XSpray Pharma AB: Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development | 466 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc... ► Artikel lesen | |
| 09.07.24 | Xspray Pharma AB: Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose | 379 | Business Wire | Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose.
Xspray Pharma AB (Stockholm/Nasdaq:... ► Artikel lesen | |
| 08.05.24 | XSpray Pharma AB: Interim Report First Quarter 2024 | 226 | GlobeNewswire (Europe) | January-March 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -67,781 thousand (-34,827)Earnings per share before dilution amounted to SEK -2.17 (-1.54)Cash flow from... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 53,50 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| EVOTEC | 7,344 | +1,75 % | Das ist die Nach-Oster-Chance! Evotec, Bayer, BioNTech, Defence Therapeutics und im Fokus | Donald Trump brüskiert seine internationalen Partner, beleidigt namhafte Amerikaner und entzieht Harvard langjährig zugesagte Fördermittel. Wer hätte das gedacht? Die neue US-Regentschaft entpuppt sich... ► Artikel lesen | |
| QIAGEN | 37,610 | +0,17 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,170 | 0,00 % | Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock | ||
| SPRINGWORKS THERAPEUTICS | 44,990 | 0,00 % | EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme
Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
24.04.2025 /... ► Artikel lesen | |
| ARCELLX | 63,97 | +0,63 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 36,680 | 0,00 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| BIONTECH | 102,20 | +0,79 % | Biontech mit EILMELDUNG: Insider kaufen massenhaft Anteile - Dringend vor Börsenschluss handeln! | ||
| EDGEWISE THERAPEUTICS | 15,400 | +3,91 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| VERA THERAPEUTICS | 23,470 | +5,20 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,290 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,750 | 0,00 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
| ADMA BIOLOGICS | 22,340 | +2,71 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,190 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 5,100 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,73 % bei einem Aktienkurs von 3,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.
